Quest Diagnostics Inc vs Ishares Msci Italy ETF — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Ishares Msci Italy ETF trades at $60.66. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Ishares Msci Italy ETF pays none, and Ishares Msci Italy ETF is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | EWI | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $61.14 |
52-Week Low | $166.42 | $47.32 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
EWI trades at $60.47, down 0.2% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The stock is near key resistance at $61, with support at $60. Recent news highlights Italy's economic recovery narrative and a 52-week high, though financial ratios are currently unavailable for detailed fundamental assessment.
The outlook is cautiously optimistic given technical strength and positive European market sentiment, but risks include Italy's stagflationary conditions and energy price volatility. Investment appeal hinges on continued economic improvement and resolution of macroeconomic headwinds impacting European equities.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →